Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2004-09-02
2009-10-20
Aeder, Sean E (Department: 1642)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
Reexamination Certificate
active
07604994
ABSTRACT:
Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. Cells may be selected for expression of activation-induced cytidine deaminase (AID), stimulated to produce AID, or manipulated to express AID for further enhancement of hypermutability. These methods are useful for generating genetic diversity within immunoglobulin genes directed against an antigen of interest to produce altered antibodies with enhanced biochemical activity. Moreover, these methods are useful for generating antibody-producing cells with increased level of antibody production.
REFERENCES:
patent: 4376110 (1983-03-01), David et al.
patent: 4720459 (1988-01-01), Winkelhake
patent: 5530101 (1996-06-01), Queen et al.
patent: 6808894 (2004-10-01), Nicolaides et al.
patent: 2003/0170895 (2003-09-01), Grasso et al.
patent: WO 02/37967 (2002-05-01), None
patent: WO 02/054856 (2002-07-01), None
patent: WO 02/054856 (2002-07-01), None
patent: WO 02/0524856 (2002-07-01), None
patent: WO 03/061363 (2003-07-01), None
patent: WO 03/061363 (2003-07-01), None
Martin et al (Nature, Feb. 14, 2002, 415:802-806).
Teng et al (Biochem. J., 1982, 203:471-476).
Muto et al (Genomics, Aug. 15, 2000, 68:85-88).
Gao et al (J. Immunol., Aug. 15, 2001, 167(4) 2011-2018).
Zhang et al (International Immunology, Sep. 13, 2001, 13(9): 1175-1184).
Kirikae et al (Int. J. Immunopharmac. (19)5:255-262), (1997).
Burgess et al. (J. Cell Biol. 111:2129-2138, 1990).
Lazar et al. (Mol. Cell Biol. 8:1247-1252, 1998).
Borrebaeck et al (PNAS, Mar. 1988, 85: 3995-3999).
Borrebaeck et al (PNAS, Mar. 1988, 85: 3995-3999).
Gao et al (J. Immunol. Aug. 15, 2001, 167(4): 2011-2018).
Sequence comparison, (2007).
Drummond, J.T., et al., “Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells,”Science, 1995, 268, 1909-1912.
Drummond, J.T., et al., “Cisplatin and adriamycin resistance are associated with MutLα and mismatch repair deficiency in an ovarian tumor cell line,”J. Biol. Chem., 1996, 271, 19645-19648.
Emery, S.C., et al., “Strategies for humanizing antibodies,” in Antibody Engineering, Borrebaeck, C.A.K. (Ed.),Oxford University Press, NY, 1995, 159-183.
Eshleman, J.R., et al., “Mismatch repair defects in human carcinogenesis,”Hum. Mol. Genet., 1996, 5, 1489-1494.
Fiedler, U., et al., “High-level production and long-term storage of engineered antibodies in transgenic tobacco seeds,”Bio/Technology, 1995, 13, 1090-1093.
Frigerio, L., et al., “Assembly, secretion, and vacuolar delivery of a hybrid immunoglobulin in plants,”Plant Physiol., 2000, 123, 1483-1494.
Galfre, G., et al., “Antibodies to major histocompatibility antigens produced by hybrid cell lines,”Nature, 1977, 266, 55052.
Gefter, M.L., et al., “A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells,”Somatic Cell Genet., 1977, 3(2), 231-236.
Galio, L., et al., “ATP hydrolysis-dependent formation of a dynamic ternary nucleoprotein complex with MutS and MutL,”Nucl. Acids Res., 1999, 27(11), 2325- 2331.
Glaser, V., “Can ReoPro repolish tarnished monoclonal therapeutics?,”Nat. Biotechnol., 1996, 14, 1216-1217.
Khazaeli, M.B., et al., “Human immune response to monoclonal antibodies,”J. Immunother., 1994, 15, 42-52.
Kitagawa, T., et al., “Enzyme coupled immunoassay of insulin using a novel coupling reagent,”J. Biochem, 1976, 79, 233-236.
Köhler, G., et al., “Continuous cultures of fused cells secreting antibody of predefined specificity,”Nature, 1975, 256, 495-497.
Kozbor, D., et al., “The production of monoclonal antibodies from human lymphocytes,”Immunology Today, 1983, 4(3), 72-79.
Lerner, E.A., “How to make a hybridoma,”Yale J. of Biol. Med., 1981, 54, 387-402.
Liu, T., et al., “Microsatellite instability as a predictor of a mutation in a DNA mismatch repair gene in familial colorectal cancer,”Genes Chromosomes Cancer, 2000, 27, 17-25.
Modrich, P., “Mismatch repair, genetic stability, and cancer,”Science, 1994, 266, 1959-1960.
Muramatsu, M., et al., “Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme,”Cell, 2000, 102, 553-563.
Muramatsu, M., et al., “Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells,”J. of Biol. Chem., 1999, 274(26), 18470-18476.
Muto, T., et al., “Isolation, tissue distribution, and chromosomal localization of the human activation-induced cytidine deaminase (Aid) gene,”Genomics, 2000, 68, 85-88.
Neuberger, M., et al., “Monoclonal antibodies. Mice perform a human repertoire,”Nature, 1997, 386, 25-26.
Nicolaides, N.C., et al., “A naturally occurringhPMS2mutation can confer a dominant negative mutator phenotype,”Mol. Cell. Biol., 1998, 18(3), 1635-1641.
Nicolaides, N.C., et al., “Analysis of the 5' region of PMS2 reveals heterogeneous transcripts and a novel overlapping gene,”Genomics, 1995, 29, 329-334.
Nicolaides, N.C., et al., “Genomic organization of the human PMS2 gene family,”Genomics, 1995, 30, 195-206.
Nicolaides, N.C., et al., “The Jun family members, c-Jun and JunD, transactivate the human c-mybpromoter via an Ap-1 like element,”J. Biol. Chem., 1992, 267, 19665-19672.
Okazaki, I.-M., et al., “The AID enzyme induces class switch recombination in fibroblasts,”Nature, 2002, 416, 340-345.
Palombo, F., et al., “Mismatch repair and cancer,”Nature, 1994, 36, p. 417.
Papadopoulos, N., et al., Mutation of a mutL homolog in hereditary colon cancer,Science, 1993, 1625-1629.
Parsons, R., et al., “Hypermutability and mismatch repair deficiency in RER+ tumor cells,” 1993, 75, 1227-1236.
Perucho, M., “Cancer of the microsatellite mutator phenotype,”Biol. Chem., 1996, 377, 675-684.
Petersen, S., et al., “AID is required to initiate Nbs1/γ-H2AX focus formation and mutations at sites of class switching,”Nature, 2001, 414, 660-665.
Petersen-Mahrt, S.K., et al., “AID mutatesE. colisuggesting a DNA deamination mechanism for antibody diversification,”Nature, 2002, 418, 99-103.
Prolla, T.A., et al., “MLH1, PMS1, and MSH2 interaction during the initiation of DNA mismatch repair in yeast,”Science, 1994, 264, 1091-1093.
Reff, M.E., “High-level production of recombinant immunoglobulins in mammalian cells,”Curr. Opin. Biotechnol., 1993, 4, 573-576.
Revy, P., et al., “Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the hyper-lgM syndrome (HIGM2),”Cell, 2000, 102, 565-575.
Saez-Ilorens, X.E., et al., “Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia,”Pediat. Infect. Dis. J, 1998, 17(9), 787-791.
Shield, C.F., et al., “A cost-effectiveness analysis of OKT3 induction therapy in cadaveric kidney transplantation,”Am. J. Kidney Dis., 1996, 27, 855-864.
Shields, R.L., et al., “Anti-IgE monoclonal antibodies that inhibit allergen-specific histamine release,”Int. Arch. Allergy Immunol., 1995, 107, 412-413.
Strand, M., et al., “Destabilization of tracts of simple repetitive DNA in yeast by mutations affecting DNA mismatch repair,”Nature, 1993, 365, 274-276.
Su, S.S., et al., “Mispair specificity of methyl directed DNA mismatch corrections in vitro,”J. Biol. Chem., 1988, 263(14), 6829-6835.
Thorell, et al., Radioimmunoassay and Related Techniques: Methodology and Clinical Applications,The C.V. Mosby Co., 1978, p. 288.
Weiner, L.M., “Monoclonal antibody therapy of cancer,”Semin. In Oncol
Grasso Luigi
Nicolaides Nicholas C.
Sass Philip M.
Aeder Sean E
Morphotek Inc.
Woodcock & Washburn LLP
LandOfFree
Genetically altered antibody-producing cell lines with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Genetically altered antibody-producing cell lines with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genetically altered antibody-producing cell lines with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4109946